| Title: | Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: A long-term prospective cohort study |
| Journal: | Digestive and Liver Disease |
| Published: | 24 Nov 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39581836/ |
| DOI: | https://doi.org/10.1016/j.dld.2024.11.002 |
Publication 14267
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
PURPOSE: To examine the mortality risk associated with metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD type, lean/non-lean MASLD and different cardiometabolic risk factors (CMRFs) in patients with inflammatory bowel disease (IBD) based on a long-term prospective cohort.</p>
METHODS: Prevalent IBD patients at baseline who were free of alcoholic liver disease, cancer and hepatitis B/C virus seropositive were included (N=4622). MASLD, MASLD type [pure MASLD, MASLD with increased alcohol intake (MetALD)], lean/non-lean MASLD and CMRFs at baseline were defined according to the latest criteria proposed by AASLD and EASL. Primary outcome was all-cause mortality. Cox proportional hazard model was used to examine the association.</p>
RESULTS: Overall, 1,763 (38.1%) were diagnosed with MASLD. During a median of 13.3-year follow-up, 451 all-cause deaths were identified. Compared with IBD-only patients, those with MASLD had a 58% excess risk of mortality (HR=1.58, 95%CI:1.07-2.32). Furthermore, as number of CMRFs increased in MASLD patients, mortality risk was significantly increased (Ptrend=0.005), with a 85% and 83% higher risk in MASLD with 3 CMRFs (HR=1.85, 95%CI:1.20-2.85) and ≥4 CMRFs (HR=1.83, 95%CI:1.16-2.89) versus IBD-only patients. Specifically, similar elevated mortality risk was observed in either pure MASLD (HR= 1.62, 95%CI:1.09-2.43) or MetALD (HR=2.03, 95%CI:1.24-3.32). Moreover, the excess mortality risk was both indicated in lean (HR=3.14, 95%CI:1.57-6.29) and non-lean MASLD (HR=1.67, 95%CI:1.12-2.48).</p>
CONCLUSIONS: MASLD, either pure MASLD or MetALD, as well as lean/non-lean MASLD, is associated with increased mortality risk in IBD patients, with greater risk as number of cardiometabolic risk factors increased and evidently higher risk in lean MASLD patients.</p>
11 Keywords
- Adult
- Cardiometabolic Risk Factors
- Fatty Liver
- Female
- Humans
- Inflammatory Bowel Diseases
- Male
- Middle Aged
- Proportional Hazards Models
- Prospective Studies
- Risk Factors
6 Authors
- Qian Zhang
- Yutao Wang
- Si Liu
- Shengtao Zhu
- Peng Li
- Shanshan Wu
1 Application
| Application ID | Title |
|---|---|
| 74444 | Common risk factors and prognosis of inflammatory bowel disease and irritable bowel syndrome |
Enabling scientific discoveries that improve human health